Developing CSCO Lung Cancer Practice Guidelines Stratified by Resource Availability and Treatment Value

著者: Zhou, Qing, Wu, Yi-Long
出版年 J Glob Oncol (2016)

Clinical trials of tyrosine kinase inhibitors for lung cancer in China: a review

著者: Su, Shan, Wu, Yi-Long
出版年 J Hematol Oncol (2017)

Immunotherapy in the Asiatic population: any differences from Caucasian population?

著者: Peng, Lunxi, Wu, Yi-Long
出版年 J Thorac Dis (2018)

Surgery in oligometastatic NSCLC patients in the targeted therapy era

著者: Zhang, Qi, Wu, Yi-Long
出版年 Lung Cancer Manag (2016)

Spatial Pattern and Dynamic Change of Vegetation Greenness From 2001 to 2020 in Tibet, China

著者: Fugen Jiang, Fugen Jiang, Fugen Jiang, Muli Deng, Muli Deng, Muli Deng, Yi Long, Yi Long, Yi Long, Hua Sun, Hua Sun, Hua Sun
出版事項 2022-04-01

Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence

著者: E-E Ke, Yi-Long Wu
出版事項 2016-06-01

An Efficient Synthesis of 5-Amido-3-Hydroxy-4-Pyrones as Inhibitors of Matrix Metalloproteinases

著者: Yan, Yi-Long, Cohen, Seth M.
出版事項 2007

1,3-Dimethyl 5-(4,4,5,5-tetra­methyl-1,3,2-dioxaborolan-2-yl)benzene-1,3-dicarboxyl­ate

著者: Yi, Long-tao, Liu, Zhi-qiang
出版事項 2012

Novel agents and strategies for overcoming EGFR TKIs resistance

著者: Niu, Fei-Yu, Wu, Yi-Long
出版事項 2014

Personalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinib

著者: Niu, Fei-Yu, Wu, Yi-Long
出版年 Onco Targets Ther (2015)

Insight into early-phase trials for lung cancer in the United States

著者: Yang, Jin-Ji, Wu, Yi-Long
出版年 Chin J Cancer (2015)

Variable density of CD8+ and CD25+ programmed cell death-1 (PD-1) ligand (PD-L1) CD4+ T cells within the tumor microenvironment causes differential responses to the PD-1/PD-L1 bloc...

著者: Wu, Si-Pei, Wu, Yi-Long
出版年 J Immunother Cancer (2015)

CSCO joins ESMO Open—Cancer Horizons

著者: Zielinski, Christoph C, Wu, Yi-Long
出版年 ESMO Open (2016)

Prevalence of driver mutations in non-small-cell lung cancers in the People’s Republic of China

著者: Gou, Lan-Ying, Wu, Yi-Long
出版年 Lung Cancer (Auckl) (2014)

Misuse of Pirated Drugs: Why China? What Is Next?

著者: Sun, Hui-wen, Wu, Yi-Long
出版年 J Glob Oncol (2016)

Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China

著者: Liu, Si-Yang, Wu, Yi-Long
出版年 J Hematol Oncol (2017)

Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence

著者: Ke, E-E, Wu, Yi-Long
出版年 Ther Adv Respir Dis (2016)

Adjuvant TKIs: still an optimal choice

著者: Liu, Si-Yang, Wu, Yi-Long
出版年 J Thorac Dis (2018)

Personalized adjuvant treatment: go through the past to the future

著者: Liu, Si-Yang, Wu, Yi-Long
出版年 J Thorac Dis (2019)

Biomarker for personalized immunotherapy

著者: Liu, Si-Yang, Wu, Yi-Long
出版年 Transl Lung Cancer Res (2019)